Danaher (DHR) Benefits From Business Strength Amid Risks
Danaher (DHR) benefits from strength in the clinical diagnostics business, Abcam buyout and pro-investor policies. However, softness in its Instrument unit is concerning.
Betting Big: 3 Dividend Stocks My Family And I Are Buying Aggressively
Market corrections happen under almost every president, and stock performance is not tied to political parties. Currently, inflation remains the key driver of market movements. Focus on undervalued opportunities in any market condition. Consistent investment in solid stocks is more effective than trying to time the market. Three key stocks in our portfolios demonstrate resilience and growth potential, offering a mix of dividend growth and value despite current market challenges.
Danaher (DHR) Q2 Earnings Beat, Biotechnology Sales Dip Y/Y
Danaher's (DHR) second-quarter earnings and revenues surpass estimates. However, the company's performance reflects a decrease in core sales in the Biotechnology segment.
Danaher Stock Soars on Q2 Earnings Beat
Danaher Corp. (DHR) beat analysts' expectations on the top and bottom lines with its second-quarter results, sending shares higher in intraday trading Tuesday.
Here's Why Danaher Stock Surged Today
The pandemic has created a lot of noise around Danaher's revenue growth, but the dust looks set to settle in 2024. Core revenue and margins were better than expected in the second quarter.
Here's What Key Metrics Tell Us About Danaher (DHR) Q2 Earnings
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher Corporation (DHR) Q2 2024 Earnings Call Transcript
Danaher Corporation (NYSE:DHR ) Q2 2024 Earnings Conference Call July 23, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer M. Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Jack Meehan - Nephron Research Rachel Vatnsdal - J.P.
Danaher Stock Surges. More Than Earnings Are Driving It Higher.
Danaher reports second-quarter adjusted earnings of $1.72 a share on revenue of $5.74 billion.
Danaher (DHR) Q2 Earnings and Revenues Beat Estimates
Danaher (DHR) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $2.05 per share a year ago.
Danaher beats Q2 profit estimates on strength in medical testing business
Danaher beat Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by strong demand for its genetic testing services, sending shares of the life sciences firm up nearly 8% in premarket trading.
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher Q2: Inventory Overhang, But Low Expectations Limit Downside
Danaher Corporation stock saw a high single-digit percentage increase from April to mid-June, but has since given up most of the gains. Concerns about inventory destocking in the bioprocessing market have impacted investor sentiment, but expectations are already priced in. Despite short-term challenges, Danaher's medium to long-term prospects remain positive, with good growth starting FY25.
